Last reviewed · How we verify
FluMist Quadrivalent (2017-2018)
FluMist Quadrivalent is a live attenuated influenza vaccine that stimulates an immune response in the nasal passages to prevent influenza infection.
FluMist Quadrivalent (2017-2018) is a live attenuated influenza vaccine (LAIV) developed by MedImmune LLC for the prevention of influenza. It is administered intranasally and contains four strains of the influenza virus. The vaccine is designed to stimulate an immune response in the nasal passages, where the virus typically enters the body. Despite its effectiveness, FluMist Quadrivalent has faced challenges, including concerns over efficacy in certain age groups and a lack of an FDA label. It is generally well-tolerated but can cause common side effects such as runny nose, sore throat, and fever. The vaccine is not recommended for individuals with certain medical conditions or for those who are pregnant.
At a glance
| Generic name | FluMist Quadrivalent (2017-2018) |
|---|---|
| Sponsor | MedImmune LLC |
| Drug class | Live attenuated influenza vaccine (LAIV) |
| Target | Influenza virus |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains weakened forms of the influenza virus that can replicate in the cooler temperatures of the nasal passages but not in the warmer lungs, thus stimulating an immune response without causing disease.
Approved indications
Common side effects
- Runny nose
- Sore throat
- Fever
- Headache
- Muscle aches
- Nasal congestion
Key clinical trials
- Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women (PHASE4)
- First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults (PHASE1)
- Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza (PHASE4)
- Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine (PHASE3)
- Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines (PHASE4)
- Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults (PHASE3)
- Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season (PHASE4)
- Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FluMist Quadrivalent (2017-2018) CI brief — competitive landscape report
- FluMist Quadrivalent (2017-2018) updates RSS · CI watch RSS
- MedImmune LLC portfolio CI